SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-168531
Filing Date
2023-06-16
Accepted
2023-06-16 09:02:30
Documents
12
Period of Report
2023-06-15
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d522415d8k.htm   iXBRL 8-K 29747
  Complete submission text file 0001193125-23-168531.txt   155275

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA verv-20230615.xsd EX-101.SCH 2850
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE verv-20230615_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE verv-20230615_pre.xml EX-101.PRE 11707
6 EXTRACTED XBRL INSTANCE DOCUMENT d522415d8k_htm.xml XML 3469
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 231019457
SIC: 2834 Pharmaceutical Preparations